Your session is about to expire
← Back to Search
Daratumumab + KRd for Multiple Myeloma
Study Summary
This trial is testing a new combination of drugs to treat Multiple Myeloma, which is a cancer of the plasma cells. The drugs work together to attack the cancer cells and destroy them. This new combination has shown to be effective in subjects with MM in preliminary trials.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have another cancer that is growing or spreading.I haven't used any experimental drugs or devices within the last 4 weeks.I have had moderate to severe asthma in the last 2 years.I have been active and mostly self-sufficient in the last 28 days.I have had a stroke with lasting effects.I have not had major surgery in the last 2 weeks.I do not have any unmanaged serious illnesses.I am committed to using two effective birth control methods.You have tested positive for hepatitis B or C, or human immunodeficiency virus.I am currently on medication for an infection.My lung function is less than half of what is expected for someone my age and size.I have not had targeted radiation therapy in the last 14 days.My organs are functioning well enough for treatment.I agree to use condoms during the study and for 3 months after.My multiple myeloma has spread to my brain or spinal cord.I am able to have children, tested negative for pregnancy, and agree to regular pregnancy tests.You have a disease that can be measured during the initial assessments.My multiple myeloma does not produce detectable levels of M protein.I have been treated with daratumumab or similar medications before.I am 18 years old or older.I have had only one treatment for multiple myeloma in the last 6 weeks.I have been newly diagnosed with multiple myeloma.I am over 70 and considered too frail for a transplant.I have been diagnosed with POEMS syndrome.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What treatments is the KRd + Daratumumab regimen typically prescribed for?
"Ocular inflammation, a sympathetic nervous system disorder, and retinal vein occlusion can be addressed with the combined treatment of Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab provided two earlier chemotherapy regimens have been tried."
What are the results of previous investigations involving Carfilzomib, lenalidomide, dexamethasone (KRd) in conjunction with Daratumumab?
"Presently, there are 752 trials assessing the effects of Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab with 170 at Phase 3. While much research is conducted within Joliet Illinois, 26228 other clinical sites worldwide have launched investigations for this combination therapy."
Is there availability for participants in this experiment?
"Unfortunately, this trial has ceased accepting candidates. It was first published on November 12th 2019 and last updated October 26th 2022. However, there are 807 clinical trials for multiple myeloma and 752 studies for Carfilzomib-lenalidomide-dexamethasone plus Daratumumab actively recruiting participants."
How many participants have been recruited to participate in this clinical trial?
"This medical trial is no longer seeking enrolment. It first appeared on 11/12/2019, and the latest update was made 10/26/2022. However, there are 807 clinical trials actively recruiting participants with multiple myeloma, and 752 studies searching for individuals to participate in Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab treatments."
Does the Food and Drug Administration (FDA) sanction Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab?
"Carfilzomib, lenalidomide and dexamethasone (KRd) in combination with Daratumumab has been evaluated for safety in clinical trials, awarding it a score of 2 on our scale. There remains no data confirming the efficacy of KRd + Dara as an intervention."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger